Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4137935 | Revista Española de Patología | 2012 | 15 Pages |
Abstract
Although this field of research is constantly evolving, with data available at the present time, this panel of experts recommends that all patients with advanced NSCLC of non-squamous cell subtype, or non-smokers regardless of the histological subtype, should be tested for EGFR gene mutations within a maximum of 7 days subsequent to the histopathological confirmation of the diagnosis. Participating laboratories must comply with external quality controls. However, at present, ALK gene rearrangements should only be tested in the context of a clinical trial, although the promising results obtained to date would suggest that its routine testing in patients with no EGFR mutations will be justified in the near future. Lastly, routine testing for other molecular abnormalities is not considered necessary in current clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
José Javier Gómez, Javier de Castro, Ángel Concha, Enriqueta Felip, Dolores Isla, Fernando López-RÃos, Luis Paz-Ares, José RamÃrez, Julián Sanz, Pilar Garrido,